Insulin Detemir and Octreotide Interaction

Drug interaction information between Insulin Detemir and Octreotide.

Insulin Detemir and Octreotide have a documented moderate interaction in FDA labeling.

FDA drug labeling documents a moderate-severity interaction between Insulin Detemir and Octreotide. This page displays the available source-record category and label text. The category is not an individual risk estimate or medication-combination direction.

Drug A

Insulin Detemir

Long-Acting Insulin

Drug B

Octreotide

Somatostatin Analog

How They Interact

Octreotide can lower blood sugar, which adds to the effect of insulin and makes low blood sugar more likely.

Frequently Asked Questions

What SPL severity band is on file for Insulin Detemir + Octreotide?

Compiled FDA labeling labels this pair moderate. That is a source-record field, not an individual medication-combination decision.

Which drug in this pair has the larger labeled-interaction portfolio?

Octreotide has 14 labeled pairs on file vs Insulin Detemir's 11. In the moderate band specifically: Insulin Detemir has 3 (also Fluoxetine, Pramlintide); Octreotide has 9 (also Insulin Aspart, Insulin Degludec, Insulin Glargine, Insulin Glulisine).

What mechanism field is on file for Insulin Detemir and Octreotide?

Octreotide can lower blood sugar, which adds to the effect of insulin and makes low blood sugar more likely.

Octreotide's labeled portfolio outnumbers Insulin Detemir

SPL source-record counts only. This page's band is moderate · classes on file: Insulin Detemir (Long-Acting Insulin); Octreotide (Somatostatin Analog).

Insulin Detemir

0 major · 3 moderate · 8 minor · 11 total

Octreotide

0 major · 9 moderate · 5 minor · 14 total

Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. This registry does not provide individual medication-combination directions.